Nutritional Risk Status Predicts Overall Survival of Mexican Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Campos-Gomez, S. [1 ]
Valdez-Andrade, J. J. [1 ]
Esquivel-Gutierrez, J. [1 ]
Jaimes Alpizar, E. [1 ]
Pacheco-Cuellar, G. [1 ]
Campos-Gomez, K. [1 ]
机构：
[1] Ctr Oncol Estatal Issemym, Thorac Oncol Unit, Toluca De Lerdo, Mexico
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
nutrition risk; lung cancer; prognosis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P09.11
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [41] EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer
    Ferraro, B
    Bepler, G
    Sharma, S
    Cantor, A
    Haura, EB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 1921 - 1926
  • [42] RETROSPECTIVE ANALYSIS OF CLINICAL FEATURES OF 5-YEAR-SURVIVAL PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Hirashima, T.
    Okamoto, N.
    Suzuki, H.
    Morishita, N.
    Tamiya, M.
    Shiroyama, T.
    Kondoh, Y.
    Ryota, N.
    Kawase, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 113 - 113
  • [43] Comorbidity and survival in advanced non-small cell lung cancer (NSCLC) veteran patients
    Chang, V. T.
    Hoover, D. R.
    Cogswell, J.
    Cholankeril, M.
    Badin, S.
    Yang, W.
    Yan, H.
    Gonzalez, M. L.
    Einhorn, J.
    Kasimis, B. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Aggarwal, Charu
    Marmarelis, Melina E.
    Hwang, Wei-Ting
    Scholes, Dylan G.
    McWilliams, Tara L.
    Singh, Aditi P.
    Sun, Lova
    Kosteva, John
    Costello, Michael R.
    Cohen, Roger B.
    Langer, Corey J.
    Doucette, Abigail
    Gabriel, Peter N.
    Shulman, Lawrence N.
    Rendle, Katharine A.
    Thompson, Jeffrey C.
    Bekelman, Justin E.
    Carpenter, Erica L.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [45] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Crawford, Jeffrey
    Denduluri, Neelima
    Patt, Debra
    Jiao, Xiaolong
    Morrow, Phuong Khanh
    Garcia, Jacob
    Barron, Richard
    Lyman, Gary H.
    SUPPORTIVE CARE IN CANCER, 2020, 28 (02) : 925 - 932
  • [46] IMPROVED SURVIVAL FOR PATIENTS WITH ADVANCED NON-SMALL-CELL CARCINOMA OF THE LUNG
    MILLER, TP
    ARIZONA MEDICINE, 1979, 36 (12) : 893 - &
  • [47] Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
    Jeffrey Crawford
    Neelima Denduluri
    Debra Patt
    Xiaolong Jiao
    Phuong Khanh Morrow
    Jacob Garcia
    Richard Barron
    Gary H. Lyman
    Supportive Care in Cancer, 2020, 28 : 925 - 932
  • [48] Does KRAS mutation status predicts for chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli, M.
    Faivre, L.
    Besse, B.
    Planchard, D.
    Caramella, C.
    Polo, V.
    Pignon, J. P.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S797 - S797
  • [49] A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib
    Donovan, Michael J.
    Kotsianti, Angeliki
    Bayer-Zubek, Valentina
    Verbel, David
    Teverovskiy, Mikhail
    Cordon-Cardo, Carlos
    Costa, Jose
    Greco, F. Anthony
    Hainsworth, John D.
    Parums, Dinah V.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1518 - 1526
  • [50] Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer
    Wu, Ning
    Ge, Wenzhen
    Quek, Ruben G. W.
    Gleeson, Michelle
    Pouliot, Jean-Francois
    Dietz, Hilary
    Jalbert, Jessica J.
    Harnett, James
    Antonia, Scott J.
    FUTURE ONCOLOGY, 2022, 18 (39) : 4385 - 4397
12345